Time course of cerebrospinal fluid responses to antiretroviral therapy: Evidence for variable compartmentalization of infection

AIDS

Volumn 13, Issue 9, 1999, Pages 1051-1061

  Staprans, Silvija ^a,c,e   Marlowe, Natalia ^c   Glidden, David ^b   Novakovic Agopian, Tatjana ^a   Grant, Robert M ^a,c   Heyes, Melvyn ^d   Aweeka, Francesca ^b   Deeks, Steven ^a   Price, Richard W ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

AIDS; AIDS dementia complex; Antiviral; Cerebrospinal fluid; HIV; Meningitis; Quinolinic acid; RNA; Treatment; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; FEMALE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; LUMBAR PUNCTURE; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; QUINOLINIC ACID; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032814302     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199906180-00008     Document Type: Article

References (43)

1. 1. Navia B, Jordan B, Price R. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19:517-524.
2. 2. Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. [Review]. N Engl J Med 1995, 332:934-940.
3. 3. Price R. Management of AIDS dementia complex and HIV-1 infection of the nervous system. AIDS 1995, 9 (Suppl. A):5221-236.
4. 4. Richman D. HIV therapeutics (viewpoints). Science 1996, 272:1886-1887.
5. 5. Price R, Staprans S. Measuring the viral load in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol 1997, 42:675-678.
6. 6. Brew B, Pemberton L, Cunningham P, Law M. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997, 175:963-966.
7. 7. Ellis R, Hsia K, Spector S, et al. CSF HIV-1 RNA levels are elevated in neurocognitively impaired individuals. Ann Neurol 1997, 42:679-688.
8. 8. McArthur J, McClernon D, Cronin M, et al. Relationship between HIV-associated dementia and viral load in CSF and brain. Ann Neurol 1997, 42:689-698.
9. 9. Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol 1998; 4:90-94.
10. 10. Pialoux G, Fournier S, Moulignier A, Poveda J-D, Clavel F, Dupont B. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir [letter]. AIDS 1997, 11:1302-1303.
11. 11. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997, 175:434-437.
12. 12. Gisslen M, Hagberg L, Svennerholm B, Norkrans G. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy [letter]. AIDS 1997, 11:1194.
13. 13. Gisslen M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study. J Acquired Immune Defic Syndr Hum Retrovirol 1998, 17:291-295.
14. 14. Gisslen M, Norkrans G, Svennerholm B, Hagberg I. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but nut in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir [letter]. AIDS 1998, 12:114-116.
15. 15. Stellbrink H, Eggers C, van Lunzen J, Albrecht H, Greten H. Rapid decay in the cerebrospinal fluid during antiretroviral combination therapy [letter]. AIDS 1998, 11:1655-1657.
16. 16. Iftimovici E, Rabian C, Burgard M, Peytavin G, Rouzioux C, Viard J-P. Longitudinal comparison of HIV-1 RNA burden in plasma and cerebrospinal fluid in two patients starting triple combination antiretroviral therapy [letter]. AIDS 1998, 12:535-537.
17. 17. Foudraine N, Hoetelmans R, Lange J, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
18. 18. Foster RH, Faulds D. Abacavir. Drugs 1998, 55:729-736; discussion 737-738.
19. 19. Heyes MP, Morrison PF. Quantification of local du novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J Neurochem 1997, 68:280-288.
20. 20. Heyes MP, Saito K, Crowley J, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurologic disease. Brain 1992, 115:1249-1273.
21. 21. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977, 37:385-390.
22. 22. Price RW, Sidtis JJ. Evaluation of the AIDS dementia complex in clinical trials. J AIDS 1990, 3 (Suppl. 2):S51-60.
23. 23. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. [Review]. Neurology 1991, 41:778-785.
24. 24. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurologic status. Ann Neurol 1991, 29:202-209.
25. 25. Deeks S, Barditch-Crovo P, Lietman P, et al. The safety, pharmacokinetics and antiretroviral activity of intravenous PMPA, a novel anti-HIV therapy, in HIV-infected adults. A randomized, double blinded, placebo controlled phase I/II trial. Antimicrob Agents Chemother 1998 (in press).
26. 26. Cinque P, Vago L, Ceresa D, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998, 12:389-394.
27. 27. Morris L, Silber E, Sonnenberg P, et al. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis 1998, 177:473-476.
28. 28. Martin C, Albert J, Hannson P, Pehrsson P, Link H, Sonnerborg A. Cerebrospinal fluid mononunuclear cell counts influente CSF HIV-1 RNA levels. J Acquired Immune Defic Syndr Hum Retrovirol 1998, 17:214-219.
29. 29. Di Stefano M, Monno L, Fiore JR, et al. Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS 1998, 12:737-743.
30. 30. Di Stefano M, Monno L, Fiore JR, Angarano G. In vivo evidence of HIV-1 productive infection in cerebrospinal fluid of patients with HIV-1 encephalopathy [letter]. AIDS 1997, 11:698-699.
31. 31. Perelson A, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
32. 32. Brinkman K, Kroon F, Hugen PW, Burger DM. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients [letter]. AIDS 1998, 12:537.
33. 33. Haworth S, Christofalo B, Anderson R, Dunkle L. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquired Immune Defic Syndr Hum Retrovirol 1998, 17:235-238.
34. 34. Stahle L, Martin C, Svensson J. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet 1997, 350:1823.
35. 35. Rolinski B, Bogner J, Sadri I, Wintergerst U, Goebel F. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquired Immune Defic Syndr 1997, 15:192-197.
36. 36. Price R, Aweeka F, Bellibas S, et al. Pharmacokinetics of Abacavir (1592U89) in cerebrospinal fluid (CSF) using multiple lumbar punctures of few subjects and 'sparse sampling' techniques. 12th World AIDS Conference. Geneva, 1999 [Poster number 42271].
37. 37. Aweeka F, Jayewardene A, Staprans S, et al. Failure to detect nelfinavir in the cerebrospinal fluid (CSF) of HIV-1-infected patients with and without AIDS dementia complex. J Acquired Immune Defic Syndr Hum Retrovirol 1999; 20:39-43.
38. 38. Wiley C, Soontornniyomkij V, Radhakrishnan L, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998, 8:277-284.
39. 39. Dickson D, Lee S. Microglia and HIV-related CNS neuropathology: an update. J Neuro-AIDS 1995, 1:57-83.
40. 40. O'Brien W. Genetic and biological basis of HIV-1 neurotropism. In HIV, AIDS and the Brain. Edited by Price R, Perry S. New York: Raven Press Ltd.; 1994:47-70.
41. 41. Hogg K, Phillips P, Forrest D, et al. Markedly declining incidence of AIDS in persons treated with antiretroviral therapy from 1994-1996. 12th World AIDS Conference. Geneva, 1998. [Abstract 12142].
42. 42. Moore R, Keruly J, Gallant J, Chaisson R. Decline in mortality rates and opportunistic disease with combination antiretroviral therapy. 12th World AIDS Conference. Geneva, 1998 [Abstract 22374].
43. 43. Sactor N, Skolasky R, Esposito D, et al. Combination antiretroviral therapy including protease inhibitors improves psychomotor speed performance in HIV infection. Neurology 1998, 50 (Suppl. 4):A248-249.